Key Market Indicators
Sales of beta-blocking medicines in Austria are set to reach $25 million by 2026. This figure is down from the 2021 sales of $37 million, a decrease of 6.5% year on year. Since 2015, the Austrian market has declined by an average of 5% each year. In 2021, Austria was the 12th largest market for beta-blocking medicines, behind Portugal, which recorded sales of $37 million. Italy, Canada and Australia respectively were numbers 2, 3 and 4 in the ranking.
